{"gene":"MMP13","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":1997,"finding":"The MMP13 gene is composed of 10 exons and 9 introns spanning over 12.5 kb. Its promoter contains a functional AP-1 site responsible for inducibility by tumor promoter TPA, an OSE-2 (osteoblast-specific element), a PEA-3 consensus sequence, and a TGF-β inhibitory element. DNA binding analysis confirmed formation of specific complexes between MMP13 promoter AP-1 sequences and nuclear proteins.","method":"Genomic cloning, nucleotide sequencing, transient transfection with CAT reporter constructs, DNA binding/EMSA with nuclear extracts","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 — direct promoter characterization with functional reporter assays and DNA binding validation in multiple cell lines","pmids":["9119388"],"is_preprint":false},{"year":2004,"finding":"RUNX2 overexpression in articular chondrocytes increases MMP-13 promoter activity and protein expression; FGF2 activates RUNX2 via MEK/ERK phosphorylation (~2-fold increase in RUNX2 phosphorylation), synergistically upregulating MMP-13. MEK/ERK inhibitors (PD98059) block this upregulation.","method":"RUNX2 overexpression, MMP-13 promoter activity assays, MEK/ERK inhibitor treatment, immunohistochemistry, Western blotting","journal":"Osteoarthritis and cartilage","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in a single study: promoter assays, pharmacological inhibition, phosphorylation analysis","pmids":["15564063"],"is_preprint":false},{"year":2004,"finding":"Mechanical strain induces MMP-13 expression in osteoblastic cells through MEK-ERK1/2 signaling. The strain-induced MMP-13 mRNA expression does not require de novo protein synthesis. Dominant-negative MEK1/2 mutants block this induction.","method":"Biaxial strain application, Western blotting, RT-PCR, zymography, pharmacological inhibitors (PD98059, SB203580, SP600125), dominant-negative MEK1/2 transfection","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including dominant-negative mutant validation and specific inhibitors","pmids":["15044466"],"is_preprint":false},{"year":2006,"finding":"TGF-β activates Smad2/3 in head-and-neck SCC cells, and Smad3 signaling (including basal activation) drives MMP-13 expression and invasion. Disruption of Smad signaling by dominant-negative constructs or Smad7 overexpression suppresses MMP-13 expression and invasion through Matrigel and collagen I.","method":"Adenoviral delivery of Smad7, dominant-negative Smad3, kinase-defective ALK-5; Matrigel invasion assays; xenograft models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic loss-of-function approaches combined with in vitro and in vivo invasion assays","pmids":["16407850"],"is_preprint":false},{"year":2007,"finding":"Lef1 and β-catenin synergistically upregulate MMP13 transcription in chondrocytes. A Lef1 binding site was mapped to the 3′ region of the MMP13 genomic locus; Lef1/β-catenin binding was confirmed by ChIP and EMSA. Lef1 siRNA knockdown suppressed IL-1β-mediated MMP13 expression.","method":"siRNA knockdown, ChIP, EMSA, MMP13 promoter reporter assays, plasmid transfection","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1-2 — direct promoter occupancy confirmed by ChIP and EMSA with functional siRNA validation","pmids":["17971297"],"is_preprint":false},{"year":2008,"finding":"Nitric oxide (NO) causes tyrosine nitration of MMP-13 at residue Y338, which dissociates MMP-13 from caveolin-1, promoting its release from endothelial cells. In iNOS knockout mice, less MMP-13 is released and wound healing is slower; in caveolin-1 KO mice, increased MMP-13 nitration and accelerated wound healing are observed.","method":"Mutagenesis (Y338 identification), Co-IP (MMP-13/caveolin-1 association), iNOS and caveolin-1 knockout mouse models, wound healing assays","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1-2 — specific PTM site identified with genetic KO models providing functional validation in vivo","pmids":["18495757"],"is_preprint":false},{"year":2008,"finding":"Ultrasound stimulation induces MMP-13 expression in osteoblasts via p38 and JNK signaling pathways (but not ERK). c-Fos and c-Jun bind to the AP-1 element on the MMP-13 promoter in response to ultrasound, enhancing AP-1 luciferase activity. Dominant-negative p38 or JNK mutants block this induction.","method":"Zymography, RT-PCR, AP-1 luciferase reporter assay, dominant-negative p38/JNK transfection, SB203580/SP600125 pharmacological inhibitors","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 1-2 — promoter reporter assays combined with dominant-negative mutant validation","pmids":["17941091"],"is_preprint":false},{"year":2009,"finding":"Stroma-derived MMP-13 is required for melanoma tumor growth and organ-specific metastasis. Tumor growth was significantly impaired in mmp-13−/− mice, and metastasis to lungs, liver, and heart was substantially reduced. Decreased tumor growth correlated with reduced blood vessel density and decreased blood vessel permeability.","method":"Intradermal melanoma injection in MMP-13 knockout mice, MRI measurement of vessel permeability, immunohistochemistry of vascularity","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with defined metastatic phenotype and mechanistic link to angiogenesis","pmids":["19516266"],"is_preprint":false},{"year":2009,"finding":"MMP13 amplification on chromosome 9A1 (syntenic with human 11q22) cooperates with p53 deficiency in osteosarcoma. High MMP13 expression enhances osteosarcoma cell survival; shRNA-mediated knockdown of MMP13 reduces tumor growth in immunodeficient mice.","method":"Array CGH, lentiviral shRNA knockdown, xenograft transplantation, microarray expression analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO/KD with defined tumor growth phenotype, but mechanism of survival enhancement not fully resolved","pmids":["19276372"],"is_preprint":false},{"year":2010,"finding":"p38γ isoform is activated by IL-1β and fibronectin fragments in chondrocytes but suppresses MMP-13 production; constitutively active p38γ decreases MMP-13 output while dominant-negative p38γ increases it. p38α (nuclear localized) promotes MMP-13 while p38γ (cytosolic) counteracts this.","method":"Constitutively active and dominant-negative p38γ transfection, isoform-selective inhibitors (SB203580, BIRB796), immunoblotting, ELISA, RT-PCR","journal":"Osteoarthritis and cartilage","confidence":"High","confidence_rationale":"Tier 1-2 — gain- and loss-of-function with specific isoforms using multiple methods","pmids":["20633667"],"is_preprint":false},{"year":2011,"finding":"Interstitial flow induces MMP-13 expression and cell motility in vascular smooth muscle cells via heparan sulfate proteoglycan (HSPG)-mediated FAK phosphorylation at Tyr925 and subsequent ERK1/2 activation. Disruption of HSPGs (heparinase or NDST1 silencing) or FAK inhibition abolishes this response.","method":"Heparinase treatment, NDST1 siRNA silencing, FAK inhibition/knockdown, ERK1/2 phosphorylation assays in 3D collagen culture","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal knockdown and pharmacological approaches with defined mechanistic pathway","pmids":["21246051"],"is_preprint":false},{"year":2012,"finding":"MMP-13 directly promotes tumor angiogenesis by activating focal adhesion kinase (FAK) and ERK in endothelial cells, enhancing capillary tube formation in vitro and in vivo. MMP-13 also indirectly promotes angiogenesis by stimulating VEGF-A secretion from fibroblasts and endothelial cells.","method":"Conditioned medium assays, recombinant MMP-13 treatment, capillary tube formation assays in vitro and in vivo, FAK/ERK activation measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — both direct (recombinant protein) and indirect mechanisms tested with defined signaling readouts","pmids":["22992737"],"is_preprint":false},{"year":2012,"finding":"Osterix physically interacts with Runx2 and cooperates with it to induce MMP13 expression during chondrocyte differentiation and endochondral ossification. Osterix-deficient mice arrest at the hypertrophic stage; introduction of MMP13 into Osterix-deficient limb bud cells restores matrix calcification.","method":"Global and conditional Osterix-KO mice, microarray analysis, Co-IP (Osterix-Runx2 interaction), adenoviral MMP13 rescue in deficient cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — physical interaction demonstrated by Co-IP, genetic KO with rescue experiment","pmids":["22869368"],"is_preprint":false},{"year":2013,"finding":"Chondrocyte-specific deletion of Mmp13 (Mmp13Col2ER mice) decelerates OA progression, maintains higher cartilage area/thickness and type II collagen/proteoglycan levels, and reduces chondrocyte apoptosis. Pharmacological inhibition of MMP13 with CL82198 (confirmed by ELISA to inhibit >85% activity) recapitulates these protective effects.","method":"Conditional chondrocyte-specific Mmp13 knockout (Col2CreER), meniscal-ligamentous injury OA model, ELISA-based MMP13 activity assay, histology/histomorphometry, TUNEL staining","journal":"Arthritis research & therapy","confidence":"High","confidence_rationale":"Tier 2 — clean conditional KO with multiple histological readouts plus pharmacological validation","pmids":["23298463"],"is_preprint":false},{"year":2013,"finding":"Knee loading reduces MMP13 activity in OA mouse cartilage through Rac1 GTPase-mediated p38 MAPK and NF-κB signaling. Silencing Rac1 reduces MMP13 expression and p-p38; constitutively active Rac1 increases and dominant-negative Rac1 decreases MMP13 activity.","method":"Mouse knee loading model, FRET-based Rac1 activity imaging, siRNA knockdown, constitutively active/dominant-negative Rac1 transfection, MMP13 activity assay, immunoblotting","journal":"BMC musculoskeletal disorders","confidence":"High","confidence_rationale":"Tier 2 — FRET live imaging combined with genetic gain/loss-of-function approaches","pmids":["24180431"],"is_preprint":false},{"year":2014,"finding":"MMP-13 shows substrate selectivity for collagen II over collagens I and III, binding specifically to two triple-helical peptides in Collagen Toolkit II (peptides II-44 and II-8). Binding requires the triple-helical conformation (MMP-13 cannot bind linear peptide). The hemopexin domain (not the free catalytic subunit) mediates this binding; the canonical cleavage site in collagen II is at Gly775-Leu776.","method":"Triple-helical peptide Collagen Toolkit libraries, solid-phase binding assays, proteolysis assays with recombinant proMMP-13, MMP-13, free hemopexin domain, and free catalytic subunit","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with structural domain dissection and defined cleavage site identification","pmids":["25008319"],"is_preprint":false},{"year":2014,"finding":"ANKRD1 acts as a transcriptional repressor of MMP13 via the AP-1 site on the MMP13 promoter, operating in association with nucleolin (identified by yeast two-hybrid and Co-IP). Ankrd1 deletion increases c-Jun binding to the MMP13 AP-1 site (shown by ChIP), elevates MMP13 mRNA and protein in skin and wounds.","method":"Yeast two-hybrid, Co-IP, ChIP, EMSA, MMP13 promoter activity assays, Ankrd1 KO mice, siRNA knockdown, Ankrd1 reconstitution","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including ChIP, Co-IP, and genetic KO with reconstitution","pmids":["24515436"],"is_preprint":false},{"year":2014,"finding":"GDF5 reduces MMP13 expression in human chondrocytes via induction of the canonical Wnt inhibitor DKK1. Inhibition of DKK1 by a small molecule (WAY-262621) reverses GDF5-mediated suppression of MMP13, establishing DKK1 as the intermediate mediator.","method":"Pellet mass culture system, qPCR, ELISA, Wnt pathway agonists (Wnt3a, CHIR-99021), DKK1 small molecule inhibitor (WAY-262621), siRNA knockdown","journal":"Osteoarthritis and cartilage","confidence":"High","confidence_rationale":"Tier 2 — pathway validated with both pharmacological activation and specific inhibition at multiple nodes","pmids":["24561281"],"is_preprint":false},{"year":2015,"finding":"MMP13 promotes colorectal cancer metastasis to the liver: both stromal (host) and tumor-derived MMP13 contribute to tumor cell extravasation from hepatic vasculature. MMP13 deficiency in host mice or stable MMP13 knockdown in tumor cells reduces extravasation and metastatic burden in vivo. MMP13 upregulation in steatotic liver increases metastatic burden.","method":"Splenic injection liver metastasis model in Mmp13-deficient mice, stable shRNA knockdown cell lines, whole-organ confocal microscopy, MTT/migration/invasion assays","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 2 — genetic KO host model combined with tumor-cell-specific knockdown and direct visualization of extravasation","pmids":["25880591"],"is_preprint":false},{"year":2015,"finding":"SENP2 inhibits MMP13 expression in bladder cancer cells by de-SUMOylating TBL1/TBLR1, which prevents β-catenin nuclear translocation and thereby reduces MMP13 transcriptional activation by β-catenin at the MMP13 promoter.","method":"SENP2 overexpression/knockdown, TBL1/TBLR1 SUMOylation assays, β-catenin nuclear translocation assays, luciferase promoter assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — defined PTM (de-SUMOylation) linked to downstream MMP13 regulation, single study","pmids":["26369384"],"is_preprint":false},{"year":2016,"finding":"ATF3 directly binds the proximal AP-1 motif of the MMP13 promoter in stimulated human chondrocytes at time points after transient cFOS binding has ceased, acting as a direct transcriptional activator. cFOS plays an earlier, indirect role. ATF3 expression itself is AP-1 (cFOS/cJUN)-dependent, creating a regulatory cascade.","method":"ChIP assays for promoter occupancy, siRNA-mediated ATF3 silencing, mRNA transcriptome analysis, protein synthesis inhibition experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct promoter occupancy by ChIP combined with specific siRNA silencing and transcriptome validation","pmids":["27956552"],"is_preprint":false},{"year":2016,"finding":"ETV4 directly regulates MMP13 gene transcription, and MMP13 mediates ETV4-driven proliferation, migration, invasion, and anchorage-independent growth in mammary epithelial cells. MMP13 inhibition partially blocks ETV4-induced tumor formation in immunodeficient mice.","method":"MMP13 promoter reporter constructs, gain/loss-of-function for ETV4 and MMP13 in cell lines and xenografts","journal":"Breast cancer research : BCR","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter regulation shown with functional rescue/inhibition, single study","pmids":["29996935"],"is_preprint":false},{"year":2016,"finding":"FGF23 drives MMP13 expression in OA chondrocytes through FGFR1 in a Klotho-independent manner, predominantly via MEK/ERK cascade with lesser PI3K/AKT contribution. RNA silencing of FGFR1 (but not Klotho) blocks FGF23-induced MMP13 upregulation.","method":"siRNA silencing of FGFR1 and Klotho, phosphoprotein array, immunoblotting, selective MAPK inhibitors, fluorescent MMP13 activity assay, immunohistochemistry","journal":"Osteoarthritis and cartilage","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (siRNA, inhibitors, activity assay) establishing receptor specificity","pmids":["27307356"],"is_preprint":false},{"year":2017,"finding":"DNA methylation of specific CpG sites in the RUNX2 P1 promoter controls RUNX2 expression; reduced methylation increases RUNX2 availability which transactivates MMP13. RUNX2 overexpression enhanced MMP13 promoter activity independently of MMP13 promoter methylation status.","method":"qPCR correlation in human OA chondrocytes, RUNX2 overexpression, in vitro methylation treatment of RUNX2 promoter constructs, MMP13 promoter reporter assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — epigenetic mechanism demonstrated with functional promoter assays, moderate evidence","pmids":["28798419"],"is_preprint":false},{"year":2019,"finding":"Osteocyte-derived MMP13 is required for perilacunar/canalicular remodeling (PLR) in subchondral bone. Osteocyte-specific Mmp13 ablation (DMP1-Cre) suppresses PLR, disorganizes bone extracellular matrix, and secondarily impairs cartilage homeostasis (reduced proteoglycan, altered collagen II, increased cartilage lesions), demonstrating a bone-cartilage crosstalk mediated by osteocytic MMP13.","method":"Osteocyte-specific Cre-mediated Mmp13 conditional KO (DMP1-Cre), histomorphometry, IHC, without surgical injury model","journal":"Bone research","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific genetic KO with multiple defined skeletal phenotypes in both human OA specimens and mouse models","pmids":["31700695"],"is_preprint":false},{"year":2019,"finding":"Bleomycin-induced lung fibrosis resolves more slowly and more severely in Mmp13-null mice, with decreased overall collagenolytic activity and persistent fibrotic foci. MMP13 is expressed mainly by macrophages during inflammation and fibrosis resolution phases, establishing an antifibrotic role for MMP13.","method":"Mmp13 knockout mice, bleomycin intratracheal instillation, bronchoalveolar lavage cytokine array, gelatinase activity assays, histology","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with well-defined fibrosis resolution phenotype and biochemical activity measurement","pmids":["30785343"],"is_preprint":false},{"year":2021,"finding":"MMP13 cleaves and remodels type I collagen matrix to expose cryptic ligands that bind integrin α3 (ITGA3), activating FAK and RUNX2 in mesenchymal stem cells to drive osteogenic differentiation. RUNX2 in turn binds the MMP13 promoter to upregulate MMP13, forming a positive feedback loop (MMP13/ITGA3/RUNX2).","method":"MMP13 knockdown, recombinant MMP13 pre-treatment of collagen matrix, ITGA3 expression analysis, RUNX2 ChIP on MMP13 promoter, in vivo bone formation assays","journal":"Acta biomaterialia","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro reconstitution of collagen cleavage, ChIP demonstrating RUNX2 binding to MMP13 promoter, in vivo validation","pmids":["33677160"],"is_preprint":false},{"year":2014,"finding":"Hsp90β and p130(cas) are identified as regulatory proteins that bind the AGRE site of the MMP-13 promoter in L-OA chondrocytes (identified by mass spectrometry). Silencing Hsp90β or p130(cas) significantly increases MMP-13 expression and production; combined silencing has an additive effect. IL-1β decreases p130(cas) and Hsp90β expression, providing a mechanism for cytokine-driven MMP-13 upregulation.","method":"Mass spectrometry identification of promoter-binding proteins, siRNA knockdown of Hsp90β/p130(cas)/NMP4, ELISA, RT-PCR, Western blotting","journal":"Annals of the rheumatic diseases","confidence":"Medium","confidence_rationale":"Tier 2 — mass spectrometry-identified regulatory proteins with siRNA functional validation, single study","pmids":["18593760"],"is_preprint":false},{"year":2016,"finding":"High molecular weight hyaluronic acid (HA) inhibits TNF-α-induced MMP13 expression in chondrocytes via CD44 interaction, which induces DUSP10/MKP5 (a negative regulator of p38 MAPK and JNK), thereby suppressing AP-1 transcriptional activity. CD44 blocking antibody abolishes HA-mediated MMP13 inhibition.","method":"CD44-blocking antibody, HA treatment, p38/JNK phosphorylation assays, AP-1 reporter assay, DUSP10/MKP5 expression analysis by RT-PCR, western blot, immunofluorescence","journal":"Journal of orthopaedic research","confidence":"Medium","confidence_rationale":"Tier 2 — pathway dissected with specific receptor blockade and downstream phosphatase induction, single study","pmids":["27101204"],"is_preprint":false},{"year":2008,"finding":"Angiotensin II activates MMP8 and MMP13 in atherosclerotic plaques with vulnerable phenotype, leading to increased collagen type I degradation and intra-plaque hemorrhage. ATII treatment increased MMP13 levels 2-fold and collagen I degradation by MMP13 3-fold in vulnerable upstream lesions.","method":"Extravascular device carotid artery model in ApoE KO mice with ATII infusion, immunohistochemistry for MMP8/MMP13 activity, collagen content assessment, MRI","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo mouse model with quantified enzyme activity and collagen degradation, single study","pmids":["19233360"],"is_preprint":false},{"year":2019,"finding":"IL-17A induces MMP-13 expression and activation in human aortic smooth muscle cells via TRAF3IP2-dependent JNK, p38 MAPK, AP-1, and NF-κB activation. Recombinant MMP-13 stimulates SMC migration via ERK. RECK (membrane-anchored inhibitor) overexpression attenuates MMP-13 activity (without affecting mRNA/protein), blocking IL-17A- and MMP-13-induced SMC migration.","method":"TRAF3IP2 knockdown/overexpression, recombinant MMP-13 treatment, RECK gain-of-function, kinase activation assays, SMC migration assays","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — defined signaling pathway with both upstream (TRAF3IP2) and downstream (RECK) modulation tested","pmids":["31074012"],"is_preprint":false},{"year":2017,"finding":"MMP-2 and MMP-13 have opposing roles in vasculogenic mimicry (VM) in large cell lung cancer. MMP-2 cleaves laminin-5 (Ln-5) to generate fragments that promote VM by activating EGFR/F-actin, while MMP-13 cleaves Ln-5 to generate different fragments that decrease EGFR/F-actin expression and disrupt VM formation.","method":"MMP-13 overexpression, recombinant MMP-13 treatment, 3D culture tube formation assays, xenograft tumor models, immunohistochemistry","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — both recombinant protein and overexpression approaches with defined downstream signaling, single study","pmids":["28766880"],"is_preprint":false},{"year":2014,"finding":"VEGFc/VEGFr3 signaling induces MMP13 expression in keratocytes (via MMP13 promoter luciferase assay). Keratocyte-derived MMP13 directly degrades type I collagen, creating stromal spaces that enable corneal neovascularization. A selective MMP13 inhibitor attenuates alkali-burn-induced corneal neovascularization.","method":"qRT-PCR, Western blot, in situ hybridization, luciferase MMP13 promoter assay, hydroxyproline content assay, selective MMP13 inhibitor treatment, immunohistochemistry","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 — promoter regulation, collagen degradation, and pharmacological inhibition in a defined in vivo model","pmids":["25190659"],"is_preprint":false}],"current_model":"MMP13 (collagenase-3) is a zinc-dependent extracellular endopeptidase that preferentially cleaves type II collagen at Gly775-Leu776 using its hemopexin domain for substrate recognition and its catalytic domain for cleavage; its transcription is regulated at a promoter containing functional AP-1, RUNX2/OSE-2, Lef1/β-catenin, and Smad binding sites, with positive inputs from RUNX2/Osterix, ATF3, ETV4, FGF23-FGFR1-ERK, IL-1β-TAK1, Rac1-p38α-NF-κB, and Wnt/Lef1 pathways, and negative regulation by p130(cas)/Hsp90β, ANKRD1-nucleolin, HA-CD44-DUSP10/MKP5, and p38γ; post-translationally, NO-driven Y338 nitration releases MMP13 from caveolin-1 storage in endothelial cells; in bone, osteocyte-derived MMP13 maintains perilacunar/canalicular remodeling and indirectly supports cartilage homeostasis; in tissue repair and cancer, secreted MMP13 remodels collagen ECM, promotes angiogenesis via FAK-ERK activation and VEGF-A release, and facilitates tumor cell extravasation and metastasis."},"narrative":{"teleology":[{"year":1997,"claim":"Defining the transcriptional architecture of MMP13 established that its inducibility is controlled through a modular promoter with AP-1, OSE-2, PEA-3, and TGF-β-inhibitory elements, providing the framework for understanding how diverse stimuli converge on MMP13 expression.","evidence":"Genomic cloning, CAT reporter assays, and EMSA with nuclear extracts in multiple cell lines","pmids":["9119388"],"confidence":"High","gaps":["Relative contribution of each promoter element in physiological contexts was not resolved","Chromatin-level regulation not addressed","No in vivo promoter validation"]},{"year":2004,"claim":"Demonstrating that mechanical strain and growth factor (FGF2) signals converge on MEK-ERK to activate MMP13 transcription—via RUNX2 phosphorylation in chondrocytes and direct transcriptional induction in osteoblasts—established the ERK-MAPK axis as a central upstream regulator of MMP13.","evidence":"RUNX2 overexpression with promoter assays, MEK inhibitors (PD98059), dominant-negative MEK1/2, biaxial strain in osteoblastic cells","pmids":["15564063","15044466"],"confidence":"High","gaps":["Identity of ERK substrates directly binding the MMP13 promoter beyond RUNX2 not resolved","Relative contributions of RUNX2-dependent vs. -independent ERK targets unclear"]},{"year":2006,"claim":"Showing that TGF-β/Smad3 signaling drives MMP13 expression and invasion in squamous carcinoma cells revealed a second major transcriptional axis (independent of MEK-ERK) through which MMP13 promotes cancer cell invasiveness.","evidence":"Dominant-negative Smad3, Smad7 overexpression, kinase-defective ALK-5, Matrigel invasion assays, xenografts","pmids":["16407850"],"confidence":"High","gaps":["Direct Smad3 occupancy of MMP13 promoter not shown by ChIP","Cross-talk between Smad and AP-1 pathways at MMP13 not addressed"]},{"year":2007,"claim":"Identification of a functional Lef1/β-catenin binding site and ChIP-confirmed occupancy at the MMP13 locus established the Wnt pathway as a direct transcriptional activator of MMP13, later reinforced by evidence that β-catenin nuclear translocation (regulated by SENP2/TBL1) controls MMP13 in cancer cells.","evidence":"ChIP, EMSA, siRNA knockdown of Lef1 in chondrocytes; SENP2/TBL1 SUMOylation assays and β-catenin translocation in bladder cancer cells","pmids":["17971297","26369384"],"confidence":"High","gaps":["Whether Lef1 and RUNX2 cooperate or compete at the MMP13 promoter is unknown","Wnt ligand specificity for MMP13 induction in vivo not established"]},{"year":2008,"claim":"Discovery that NO-mediated Tyr338 nitration dissociates MMP13 from caveolin-1, promoting its secretion from endothelial cells during wound healing, revealed the first post-translational mechanism controlling MMP13 release rather than transcription.","evidence":"Y338 mutagenesis, Co-IP of MMP13/caveolin-1, iNOS-KO and caveolin-1-KO mice with wound healing assays","pmids":["18495757"],"confidence":"High","gaps":["Whether Y338 nitration affects catalytic activity in addition to secretion is unknown","Applicability beyond endothelial cells not tested"]},{"year":2008,"claim":"Parallel studies revealed additional MAPK route diversity: ultrasound-induced MMP13 in osteoblasts depends on p38/JNK (not ERK), and angiotensin II activates MMP13 in atherosclerotic plaques, expanding the pathophysiological contexts of MMP13 regulation beyond cartilage and bone.","evidence":"Dominant-negative p38/JNK with AP-1 reporters in osteoblasts; ATII infusion in ApoE-KO carotid model with MMP13 IHC","pmids":["17941091","19233360"],"confidence":"High","gaps":["Stimulus-specific selection of p38/JNK vs. ERK at the MMP13 promoter not mechanistically explained","ATII-MMP13 link not validated by genetic ablation"]},{"year":2009,"claim":"MMP13-knockout host mice showed impaired melanoma growth, reduced metastasis, and decreased angiogenesis, establishing that stroma-derived MMP13 is functionally required for tumor vascularization and organ-specific metastatic colonization.","evidence":"Intradermal melanoma injection in global Mmp13-KO mice, MRI vessel permeability, IHC","pmids":["19516266"],"confidence":"High","gaps":["Specific MMP13 substrates mediating vascular permeability not identified","Tumor-cell-autonomous vs. stromal MMP13 not dissected in this model"]},{"year":2010,"claim":"Demonstrating that p38γ opposes p38α in suppressing MMP13 output in chondrocytes established isoform-specific MAPK antagonism as a fine-tuning mechanism, explaining why global p38 inhibitors do not simply reduce MMP13.","evidence":"Constitutively active and dominant-negative p38γ constructs, isoform-selective inhibitors, ELISA in chondrocytes","pmids":["20633667"],"confidence":"High","gaps":["Direct p38γ phosphorylation targets that mediate MMP13 suppression not identified","In vivo relevance of p38γ-mediated MMP13 regulation not shown"]},{"year":2012,"claim":"Recombinant MMP13 directly activates FAK and ERK in endothelial cells to promote tube formation and indirectly stimulates VEGF-A secretion, defining a dual (direct + indirect) pro-angiogenic mechanism that explains the vascular phenotype of MMP13-KO tumors.","evidence":"Recombinant MMP13 treatment, FAK/ERK phosphorylation, capillary tube assays in vitro and in vivo","pmids":["22992737"],"confidence":"High","gaps":["The MMP13 substrate(s) that generate FAK-activating ligands in endothelial cells are unidentified","Whether catalytic activity or protein-protein interaction drives FAK activation is unclear"]},{"year":2012,"claim":"Osterix physically interacts with RUNX2 (by Co-IP) and cooperates to drive MMP13 during endochondral ossification; adenoviral MMP13 rescue of Osterix-KO cells restores matrix calcification, placing MMP13 as a critical RUNX2/Osterix effector in skeletal development.","evidence":"Global and conditional Osterix-KO mice, Co-IP, adenoviral MMP13 rescue in limb bud cells","pmids":["22869368"],"confidence":"High","gaps":["Whether Osterix directly contacts the MMP13 promoter or acts solely through RUNX2 is unresolved","Osterix-RUNX2 binding interface not structurally characterized"]},{"year":2013,"claim":"Chondrocyte-specific Mmp13 deletion decelerates osteoarthritis progression (preserving collagen II and proteoglycan and reducing apoptosis), directly establishing MMP13 as a disease-driving collagenase in OA cartilage and validating it as a therapeutic target.","evidence":"Conditional Col2CreER Mmp13 KO, meniscal-ligamentous OA model, pharmacological validation with CL82198, histomorphometry","pmids":["23298463"],"confidence":"High","gaps":["Whether MMP13 inhibition is sufficient long-term or whether compensatory collagenases emerge is unknown","Anti-apoptotic effect could be indirect via ECM preservation"]},{"year":2014,"claim":"Biochemical dissection with triple-helical peptide toolkits showed MMP13 preferentially binds collagen II over collagens I/III through its hemopexin domain recognizing specific triple-helical motifs, with canonical cleavage at Gly775-Leu776, resolving the structural basis for substrate selectivity.","evidence":"Solid-phase binding with Collagen Toolkit peptide libraries, proteolysis assays with recombinant domains","pmids":["25008319"],"confidence":"High","gaps":["Full-length collagen II–MMP13 co-crystal structure unavailable","How collagen cross-linking or post-translational modifications affect recognition unknown"]},{"year":2014,"claim":"Identification of ANKRD1-nucleolin as a repressive complex at the MMP13 AP-1 site (by yeast two-hybrid, Co-IP, and ChIP) and of Hsp90β/p130Cas as repressors at the AGRE element revealed dedicated negative regulatory mechanisms that are relieved by cytokine stimulation.","evidence":"Yeast two-hybrid, Co-IP, ChIP showing increased c-Jun binding in Ankrd1-KO; mass spectrometry, siRNA of Hsp90β/p130Cas in chondrocytes","pmids":["24515436","18593760"],"confidence":"High","gaps":["Whether ANKRD1-nucleolin and Hsp90β/p130Cas interact or regulate independently is unknown","Structural basis for ANKRD1 displacement of c-Jun not resolved"]},{"year":2015,"claim":"Using MMP13-deficient hosts and tumor-cell-specific knockdown in a liver metastasis model, both stromal and tumor-derived MMP13 were shown to promote colorectal cancer extravasation, extending MMP13's metastatic role beyond melanoma to epithelial cancers with tissue-specific effects.","evidence":"Splenic injection model in Mmp13-KO mice, stable shRNA in tumor cells, whole-organ confocal imaging","pmids":["25880591"],"confidence":"High","gaps":["MMP13 substrates facilitating trans-endothelial migration not identified","Whether MMP13 acts on endothelial junctions or basement membrane in this context is unclear"]},{"year":2016,"claim":"ChIP-based temporal mapping revealed that ATF3 (not c-Fos) is the sustained direct occupant of the MMP13 AP-1 site after stimulation, with ETV4 independently shown to directly activate MMP13 transcription in breast epithelial cells, diversifying the set of known direct transcriptional activators.","evidence":"Time-resolved ChIP for ATF3/cFOS occupancy with siRNA in chondrocytes; ETV4 gain/loss-of-function with MMP13 promoter reporters in mammary cells","pmids":["27956552","29996935"],"confidence":"High","gaps":["Whether ATF3 and ETV4 cooperate in any shared cell type is unknown","Genome-wide enhancer elements driving MMP13 beyond the proximal promoter not mapped"]},{"year":2016,"claim":"FGF23 was shown to drive MMP13 in chondrocytes through FGFR1 (Klotho-independent) predominantly via MEK/ERK, and HA-CD44-DUSP10/MKP5 axis was identified as suppressing MMP13 by dephosphorylating p38/JNK, adding receptor-level specificity to both inductive and suppressive arms of MMP13 regulation.","evidence":"FGFR1/Klotho siRNA with phosphoprotein arrays; CD44 blocking antibody, DUSP10 expression analysis in chondrocytes","pmids":["27307356","27101204"],"confidence":"High","gaps":["Relative in vivo importance of FGF23 vs. FGF2 in OA-associated MMP13 upregulation not established","Whether DUSP10 directly dephosphorylates p38α at the MMP13 promoter complex is unresolved"]},{"year":2019,"claim":"Osteocyte-specific Mmp13 ablation (DMP1-Cre) impaired perilacunar/canalicular remodeling and secondarily degraded cartilage homeostasis, establishing that osteocyte-derived MMP13 maintains the bone-cartilage unit through subchondral matrix turnover.","evidence":"Conditional DMP1-Cre Mmp13 KO mice, histomorphometry, IHC of bone and cartilage","pmids":["31700695"],"confidence":"High","gaps":["Molecular signals from osteocytes to chondrocytes disrupted by PLR failure are unknown","Whether lactation-induced PLR also requires MMP13 not tested"]},{"year":2019,"claim":"Mmp13-null mice showed exacerbated bleomycin-induced lung fibrosis with reduced collagenolytic activity, revealing an anti-fibrotic role for macrophage-derived MMP13 in fibrosis resolution—opposite to its cartilage-destructive role in OA.","evidence":"Global Mmp13-KO, bleomycin model, BAL cytokine array, gelatinase activity assays","pmids":["30785343"],"confidence":"High","gaps":["Whether MMP13 directly cleaves lung collagen or acts through activation of other MMPs is not resolved","Specific macrophage subtype expressing MMP13 not identified"]},{"year":2021,"claim":"MMP13 cleavage of type I collagen exposes cryptic integrin α3 ligands that activate FAK-RUNX2, which in turn transactivates MMP13, establishing a self-amplifying positive feedback loop (MMP13→ITGA3→FAK→RUNX2→MMP13) in osteogenic differentiation.","evidence":"Recombinant MMP13 pre-treatment of collagen matrix, ITGA3 analysis, RUNX2 ChIP on MMP13 promoter, in vivo bone formation","pmids":["33677160"],"confidence":"High","gaps":["Specific cryptic collagen I peptide sequences recognized by ITGA3 not identified","Whether this feedback loop operates in pathological bone remodeling (e.g., metastatic lesions) is untested"]},{"year":null,"claim":"Key unresolved questions include the structural basis for MMP13 hemopexin domain recognition of collagen II triple helix, the identity of MMP13-generated fragments that activate endothelial FAK during angiogenesis, how tissue context (cartilage vs. lung vs. tumor stroma) determines whether MMP13 activity is destructive or protective, and whether therapeutic MMP13 inhibition can achieve tissue-selective effects.","evidence":"","pmids":[],"confidence":"Low","gaps":["No co-crystal structure of MMP13 hemopexin domain with collagen II","Angiogenic substrate fragments not identified biochemically","No systems-level model integrating transcriptional, post-translational, and feedback regulation of MMP13 across tissues"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[15,26]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[13,15,25,29,32]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[5,7,11,15,18,25,26,29]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[15,24,26,32]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[13,15,24,25,26,29,32]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,3,4,9,10,14,22,30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,8,18,21]}],"complexes":[],"partners":["RUNX2","CAV1","ANKRD1","NCL","LEF1","CTNNB1","SP7","ATF3"],"other_free_text":[]},"mechanistic_narrative":"MMP13 (collagenase-3) is a zinc-dependent matrix metalloproteinase that cleaves fibrillar collagens—with marked preference for type II collagen at Gly775-Leu776—using its hemopexin domain for triple-helical substrate recognition and its catalytic domain for hydrolysis, thereby remodeling extracellular matrix in bone, cartilage, vasculature, and wound repair [PMID:25008319, PMID:23298463, PMID:31700695]. Transcription of MMP13 is driven by a promoter containing functional AP-1, RUNX2/OSE-2, Lef1/β-catenin, and Smad-responsive elements, integrating signals from MEK-ERK (via RUNX2 phosphorylation, FGF23-FGFR1, mechanical strain), p38α-JNK-NF-κB (via Rac1, IL-1β), Wnt/β-catenin (via Lef1), TGF-β-Smad3, and direct binding of ATF3 and ETV4; transcriptional repression is mediated by ANKRD1-nucleolin at the AP-1 site, Hsp90β/p130Cas at the AGRE element, p38γ antagonism, and HA-CD44-DUSP10 axis suppressing MAPK [PMID:9119388, PMID:15564063, PMID:17971297, PMID:27956552, PMID:24515436, PMID:20633667, PMID:27101204]. Post-translationally, nitric oxide–driven nitration of Tyr338 releases MMP13 from caveolin-1 storage in endothelial cells, controlling its secretion during wound healing [PMID:18495757]. In vivo, osteocyte-derived MMP13 maintains perilacunar/canalicular remodeling and cartilage integrity, chondrocyte MMP13 drives osteoarthritis cartilage destruction, macrophage-expressed MMP13 promotes lung fibrosis resolution, and stromal/tumor-derived MMP13 facilitates angiogenesis via FAK-ERK activation and VEGF-A release and enables tumor extravasation and metastasis [PMID:31700695, PMID:23298463, PMID:30785343, PMID:22992737, PMID:25880591]."},"prefetch_data":{"uniprot":{"accession":"P45452","full_name":"Collagenase 3","aliases":["Matrix metalloproteinase-13","MMP-13"],"length_aa":471,"mass_kda":53.8,"function":"Plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN. Cleaves triple helical collagens, including type I, type II and type III collagen, but has the highest activity with soluble type II collagen. Can also degrade collagen type IV, type XIV and type X. May also function by activating or degrading key regulatory proteins, such as TGFB1 and CCN2. Plays a role in wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification. Required for normal embryonic bone development and ossification. Plays a role in the healing of bone fractures via endochondral ossification. Plays a role in wound healing, probably by a mechanism that involves proteolytic activation of TGFB1 and degradation of CCN2. Plays a role in keratinocyte migration during wound healing. May play a role in cell migration and in tumor cell invasion","subcellular_location":"Secreted, extracellular space, extracellular matrix; Secreted","url":"https://www.uniprot.org/uniprotkb/P45452/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MMP13","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MMP13","total_profiled":1310},"omim":[{"mim_id":"620882","title":"SECONDARY OSSIFICATION CENTER-ASSOCIATED REGULATOR OF CHONDROCYTE MATURATION; SNORC","url":"https://www.omim.org/entry/620882"},{"mim_id":"618005","title":"CONGENITAL DISORDER OF GLYCOSYLATION WITH DEFECTIVE FUCOSYLATION 1; CDGF1","url":"https://www.omim.org/entry/618005"},{"mim_id":"613073","title":"METAPHYSEAL ANADYSPLASIA 2; MANDP2","url":"https://www.omim.org/entry/613073"},{"mim_id":"607948","title":"MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/607948"},{"mim_id":"604629","title":"MATRIX METALLOPROTEINASE 20; MMP20","url":"https://www.omim.org/entry/604629"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"urinary bladder","ntpm":10.7}],"url":"https://www.proteinatlas.org/search/MMP13"},"hgnc":{"alias_symbol":["CLG3"],"prev_symbol":[]},"alphafold":{"accession":"P45452","domains":[{"cath_id":"3.40.390.10","chopping":"118-267","consensus_level":"high","plddt":94.854,"start":118,"end":267},{"cath_id":"2.110.10.10","chopping":"293-470","consensus_level":"high","plddt":94.846,"start":293,"end":470}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P45452","model_url":"https://alphafold.ebi.ac.uk/files/AF-P45452-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P45452-F1-predicted_aligned_error_v6.png","plddt_mean":88.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MMP13","jax_strain_url":"https://www.jax.org/strain/search?query=MMP13"},"sequence":{"accession":"P45452","fasta_url":"https://rest.uniprot.org/uniprotkb/P45452.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P45452/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P45452"}},"corpus_meta":[{"pmid":"23298463","id":"PMC_23298463","title":"MMP13 is a critical target gene during the progression of osteoarthritis.","date":"2013","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23298463","citation_count":413,"is_preprint":false},{"pmid":"26931159","id":"PMC_26931159","title":"Circular RNA Related to the Chondrocyte ECM Regulates MMP13 Expression by Functioning as a MiR-136 'Sponge' in Human Cartilage Degradation.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26931159","citation_count":251,"is_preprint":false},{"pmid":"15564063","id":"PMC_15564063","title":"Regulation of MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage.","date":"2004","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/15564063","citation_count":243,"is_preprint":false},{"pmid":"18289056","id":"PMC_18289056","title":"Joint diseases and matrix metalloproteinases: a role for MMP-13.","date":"2008","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/18289056","citation_count":229,"is_preprint":false},{"pmid":"35163727","id":"PMC_35163727","title":"The Role of Matrix Metalloproteinases (MMP-8, MMP-9, MMP-13) in Periodontal and Peri-Implant Pathological Processes.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163727","citation_count":221,"is_preprint":false},{"pmid":"9119388","id":"PMC_9119388","title":"Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13).","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9119388","citation_count":169,"is_preprint":false},{"pmid":"22869368","id":"PMC_22869368","title":"Osterix regulates calcification and degradation of chondrogenic matrices through matrix metalloproteinase 13 (MMP13) expression in association with transcription factor Runx2 during endochondral ossification.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22869368","citation_count":137,"is_preprint":false},{"pmid":"22992737","id":"PMC_22992737","title":"Matrix metalloproteinase-13 (MMP-13) directly and indirectly promotes tumor angiogenesis.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22992737","citation_count":114,"is_preprint":false},{"pmid":"10967042","id":"PMC_10967042","title":"Differential expression of MT1-MMP (MMP-14) and collagenase III (MMP-13) genes in normal and wounded rat corneas.","date":"2000","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/10967042","citation_count":102,"is_preprint":false},{"pmid":"10441523","id":"PMC_10441523","title":"Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10441523","citation_count":99,"is_preprint":false},{"pmid":"31700695","id":"PMC_31700695","title":"Osteocyte dysfunction promotes osteoarthritis through MMP13-dependent suppression of subchondral bone homeostasis.","date":"2019","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/31700695","citation_count":93,"is_preprint":false},{"pmid":"19516266","id":"PMC_19516266","title":"Stromal expression of MMP-13 is required for melanoma invasion and metastasis.","date":"2009","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19516266","citation_count":90,"is_preprint":false},{"pmid":"19276372","id":"PMC_19276372","title":"MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19276372","citation_count":84,"is_preprint":false},{"pmid":"15044466","id":"PMC_15044466","title":"Mechanical strain induces collagenase-3 (MMP-13) expression in MC3T3-E1 osteoblastic cells.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15044466","citation_count":84,"is_preprint":false},{"pmid":"12885852","id":"PMC_12885852","title":"Expression of MMP-8 and MMP-13 genes in the periodontal ligament during tooth movement in rats.","date":"2003","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/12885852","citation_count":81,"is_preprint":false},{"pmid":"16407850","id":"PMC_16407850","title":"Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16407850","citation_count":79,"is_preprint":false},{"pmid":"24561281","id":"PMC_24561281","title":"GDF5 reduces MMP13 expression in human chondrocytes via DKK1 mediated canonical Wnt signaling inhibition.","date":"2014","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/24561281","citation_count":78,"is_preprint":false},{"pmid":"28120109","id":"PMC_28120109","title":"Effect of inhibiting MMP13 and ADAMTS5 by intra-articular injection of small interfering RNA in a surgically induced osteoarthritis model of mice.","date":"2017","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/28120109","citation_count":77,"is_preprint":false},{"pmid":"26817521","id":"PMC_26817521","title":"PAI-1, a target gene of miR-143, regulates invasion and metastasis by upregulating MMP-13 expression of human osteosarcoma.","date":"2016","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26817521","citation_count":72,"is_preprint":false},{"pmid":"21246051","id":"PMC_21246051","title":"Heparan sulfate proteoglycans mediate interstitial flow mechanotransduction regulating MMP-13 expression and cell motility via FAK-ERK in 3D collagen.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21246051","citation_count":69,"is_preprint":false},{"pmid":"19784544","id":"PMC_19784544","title":"Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis.","date":"2009","source":"Modern rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/19784544","citation_count":66,"is_preprint":false},{"pmid":"32854712","id":"PMC_32854712","title":"MMP-13 enzyme and pH responsive theranostic nanoplatform for osteoarthritis.","date":"2020","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/32854712","citation_count":65,"is_preprint":false},{"pmid":"27035978","id":"PMC_27035978","title":"Paclitaxel-induced epithelial damage and ectopic MMP-13 expression promotes neurotoxicity in zebrafish.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27035978","citation_count":65,"is_preprint":false},{"pmid":"31402547","id":"PMC_31402547","title":"Circ_0136474 and MMP-13 suppressed cell proliferation by competitive binding to miR-127-5p in osteoarthritis.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31402547","citation_count":65,"is_preprint":false},{"pmid":"27956552","id":"PMC_27956552","title":"Cytokine-induced MMP13 Expression in Human Chondrocytes Is Dependent on Activating Transcription Factor 3 (ATF3) Regulation.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27956552","citation_count":60,"is_preprint":false},{"pmid":"11850838","id":"PMC_11850838","title":"Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11850838","citation_count":60,"is_preprint":false},{"pmid":"29996935","id":"PMC_29996935","title":"ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis.","date":"2018","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/29996935","citation_count":56,"is_preprint":false},{"pmid":"25609201","id":"PMC_25609201","title":"Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25609201","citation_count":56,"is_preprint":false},{"pmid":"23762330","id":"PMC_23762330","title":"A feedback inhibition between miRNA-127 and TGFβ/c-Jun cascade in HCC cell migration via MMP13.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23762330","citation_count":54,"is_preprint":false},{"pmid":"32042099","id":"PMC_32042099","title":"Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.","date":"2020","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/32042099","citation_count":53,"is_preprint":false},{"pmid":"33287358","id":"PMC_33287358","title":"Gremlin-1 Promotes Metastasis of Breast Cancer Cells by Activating STAT3-MMP13 Signaling Pathway.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33287358","citation_count":52,"is_preprint":false},{"pmid":"28447732","id":"PMC_28447732","title":"Icariin inhibits MMP‑1, MMP‑3 and MMP‑13 expression through MAPK pathways in IL‑1β‑stimulated SW1353 chondrosarcoma cells.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28447732","citation_count":52,"is_preprint":false},{"pmid":"28869834","id":"PMC_28869834","title":"PKR activation causes inflammation and MMP-13 secretion in human degenerated articular chondrocytes.","date":"2017","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/28869834","citation_count":51,"is_preprint":false},{"pmid":"12009332","id":"PMC_12009332","title":"Reduction of cytokine-induced expression and activity of MMP-1 and MMP-13 by mechanical strain in MH7A rheumatoid synovial cells.","date":"2002","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12009332","citation_count":50,"is_preprint":false},{"pmid":"33251599","id":"PMC_33251599","title":"Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33251599","citation_count":49,"is_preprint":false},{"pmid":"26305372","id":"PMC_26305372","title":"SERPINE2 Inhibits IL-1α-Induced MMP-13 Expression in Human Chondrocytes: Involvement of ERK/NF-κB/AP-1 Pathways.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26305372","citation_count":49,"is_preprint":false},{"pmid":"25008319","id":"PMC_25008319","title":"The recognition of collagen and triple-helical toolkit peptides by MMP-13: sequence specificity for binding and cleavage.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25008319","citation_count":48,"is_preprint":false},{"pmid":"33031905","id":"PMC_33031905","title":"Long non-coding RNA LINC00511/miR-150/MMP13 axis promotes breast cancer proliferation, migration and invasion.","date":"2020","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/33031905","citation_count":48,"is_preprint":false},{"pmid":"28798419","id":"PMC_28798419","title":"DNA methylation of the RUNX2 P1 promoter mediates MMP13 transcription in chondrocytes.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28798419","citation_count":48,"is_preprint":false},{"pmid":"28158191","id":"PMC_28158191","title":"ATP6V1H Deficiency Impairs Bone Development through Activation of MMP9 and MMP13.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28158191","citation_count":48,"is_preprint":false},{"pmid":"23183190","id":"PMC_23183190","title":"Inhibition effect of curcumin on TNF-α and MMP-13 expression induced by advanced glycation end products in chondrocytes.","date":"2012","source":"Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23183190","citation_count":47,"is_preprint":false},{"pmid":"21567132","id":"PMC_21567132","title":"Effect of low-intensity pulsed ultrasound on MMP-13 and MAPKs signaling pathway in rabbit knee osteoarthritis.","date":"2011","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/21567132","citation_count":46,"is_preprint":false},{"pmid":"19233360","id":"PMC_19233360","title":"Activation of MMP8 and MMP13 by angiotensin II correlates to severe intra-plaque hemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable phenotype.","date":"2009","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/19233360","citation_count":45,"is_preprint":false},{"pmid":"25880591","id":"PMC_25880591","title":"Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver.","date":"2015","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25880591","citation_count":44,"is_preprint":false},{"pmid":"12351664","id":"PMC_12351664","title":"Expression of MMP-8 and MMP-13 mRNAs in rat periodontium during tooth eruption.","date":"2002","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/12351664","citation_count":43,"is_preprint":false},{"pmid":"16459052","id":"PMC_16459052","title":"TAK1 downregulation reduces IL-1beta induced expression of MMP13, MMP1 and TNF-alpha.","date":"2005","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/16459052","citation_count":42,"is_preprint":false},{"pmid":"16390465","id":"PMC_16390465","title":"Increase of MMP-13 expression in multi-stage oral carcinogenesis and epigallocatechin-3-gallate suppress MMP-13 expression.","date":"2006","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/16390465","citation_count":42,"is_preprint":false},{"pmid":"26395178","id":"PMC_26395178","title":"Overexpression of MMP13 in human osteoarthritic cartilage is associated with the SMAD-independent TGF-β signalling pathway.","date":"2015","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26395178","citation_count":41,"is_preprint":false},{"pmid":"25085584","id":"PMC_25085584","title":"Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via downregulation of MMP7 and MMP13.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25085584","citation_count":41,"is_preprint":false},{"pmid":"18495757","id":"PMC_18495757","title":"Nitric oxide elicits functional MMP-13 protein-tyrosine nitration during wound repair.","date":"2008","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/18495757","citation_count":39,"is_preprint":false},{"pmid":"19437536","id":"PMC_19437536","title":"ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19437536","citation_count":39,"is_preprint":false},{"pmid":"27356745","id":"PMC_27356745","title":"CCR4 promotes metastasis via ERK/NF-κB/MMP13 pathway and acts downstream of TNF-α in colorectal cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27356745","citation_count":39,"is_preprint":false},{"pmid":"31666602","id":"PMC_31666602","title":"Notch Signaling Regulates MMP-13 Expression via Runx2 in Chondrocytes.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31666602","citation_count":38,"is_preprint":false},{"pmid":"30785343","id":"PMC_30785343","title":"Delayed resolution of bleomycin-induced pulmonary fibrosis in absence of MMP13 (collagenase 3).","date":"2019","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30785343","citation_count":38,"is_preprint":false},{"pmid":"23473976","id":"PMC_23473976","title":"Salubrinal reduces expression and activity of MMP13 in chondrocytes.","date":"2013","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/23473976","citation_count":37,"is_preprint":false},{"pmid":"9699841","id":"PMC_9699841","title":"High levels of expression of collagenase-3 (MMP-13) in pathological conditions associated with a foreign-body reaction.","date":"1998","source":"The Journal of bone and joint surgery. British volume","url":"https://pubmed.ncbi.nlm.nih.gov/9699841","citation_count":37,"is_preprint":false},{"pmid":"16398406","id":"PMC_16398406","title":"Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma.","date":"2005","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/16398406","citation_count":36,"is_preprint":false},{"pmid":"33677160","id":"PMC_33677160","title":"Cryptic ligand on collagen matrix unveiled by MMP13 accelerates bone tissue regeneration via MMP13/Integrin α3/RUNX2 feedback loop.","date":"2021","source":"Acta biomaterialia","url":"https://pubmed.ncbi.nlm.nih.gov/33677160","citation_count":36,"is_preprint":false},{"pmid":"24515436","id":"PMC_24515436","title":"ANKRD1 acts as a transcriptional repressor of MMP13 via the AP-1 site.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24515436","citation_count":36,"is_preprint":false},{"pmid":"31067826","id":"PMC_31067826","title":"IL-1β Damages Fibrocartilage and Upregulates MMP-13 Expression in Fibrochondrocytes in the Condyle of the Temporomandibular Joint.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31067826","citation_count":36,"is_preprint":false},{"pmid":"30889876","id":"PMC_30889876","title":"Association of MMP9-1562C/T and MMP13-77A/G Polymorphisms with Non-Small Cell Lung Cancer in Southern Chinese Population.","date":"2019","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/30889876","citation_count":35,"is_preprint":false},{"pmid":"38689658","id":"PMC_38689658","title":"MMP13-targeted siRNA-loaded micelles for diagnosis and treatment of posttraumatic osteoarthritis.","date":"2024","source":"Bioactive materials","url":"https://pubmed.ncbi.nlm.nih.gov/38689658","citation_count":35,"is_preprint":false},{"pmid":"28623423","id":"PMC_28623423","title":"CXCL10 suppression of hem- and lymph-angiogenesis in inflamed corneas through MMP13.","date":"2017","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28623423","citation_count":35,"is_preprint":false},{"pmid":"26369384","id":"PMC_26369384","title":"SENP2 regulates MMP13 expression in a bladder cancer cell line through SUMOylation of TBL1/TBLR1.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26369384","citation_count":34,"is_preprint":false},{"pmid":"26517808","id":"PMC_26517808","title":"Infiltrating neutrophils increase bladder cancer cell invasion via modulation of androgen receptor (AR)/MMP13 signals.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26517808","citation_count":34,"is_preprint":false},{"pmid":"29048269","id":"PMC_29048269","title":"An improved collagen zymography approach for evaluating the collagenases MMP-1, MMP-8, and MMP-13.","date":"2017","source":"BioTechniques","url":"https://pubmed.ncbi.nlm.nih.gov/29048269","citation_count":33,"is_preprint":false},{"pmid":"31074012","id":"PMC_31074012","title":"RECK suppresses interleukin-17/TRAF3IP2-mediated MMP-13 activation and human aortic smooth muscle cell migration and proliferation.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31074012","citation_count":33,"is_preprint":false},{"pmid":"28766880","id":"PMC_28766880","title":"MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer.","date":"2017","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28766880","citation_count":33,"is_preprint":false},{"pmid":"25149157","id":"PMC_25149157","title":"Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25149157","citation_count":33,"is_preprint":false},{"pmid":"31308631","id":"PMC_31308631","title":"Activation of the P38/CREB/MMP13 axis is associated with osteoarthritis.","date":"2019","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31308631","citation_count":32,"is_preprint":false},{"pmid":"27307356","id":"PMC_27307356","title":"Fibroblast Growth Factor 23 drives MMP13 expression in human osteoarthritic chondrocytes in a Klotho-independent manner.","date":"2016","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/27307356","citation_count":32,"is_preprint":false},{"pmid":"24180431","id":"PMC_24180431","title":"Knee loading reduces MMP13 activity in the mouse cartilage.","date":"2013","source":"BMC musculoskeletal disorders","url":"https://pubmed.ncbi.nlm.nih.gov/24180431","citation_count":31,"is_preprint":false},{"pmid":"28265573","id":"PMC_28265573","title":"Autophagy Protects Advanced Glycation End Product-Induced Apoptosis and Expression of MMP-3 and MMP-13 in Rat Chondrocytes.","date":"2017","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/28265573","citation_count":30,"is_preprint":false},{"pmid":"17971297","id":"PMC_17971297","title":"Transcriptional regulation of MMP13 by Lef1 in chondrocytes.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17971297","citation_count":29,"is_preprint":false},{"pmid":"30695018","id":"PMC_30695018","title":"Golgi Membrane Protein 1 (GOLM1) Promotes Growth and Metastasis of Breast Cancer Cells via Regulating Matrix Metalloproteinase-13 (MMP13).","date":"2019","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/30695018","citation_count":29,"is_preprint":false},{"pmid":"21913037","id":"PMC_21913037","title":"Implication of MMP-9 and urokinase plasminogen activator (uPA) in the activation of pro-matrix metalloproteinase (MMP)-13.","date":"2011","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/21913037","citation_count":27,"is_preprint":false},{"pmid":"21447140","id":"PMC_21447140","title":"Expression of MMP-8 and MMP-13 in the development of periradicular lesions.","date":"2011","source":"International endodontic journal","url":"https://pubmed.ncbi.nlm.nih.gov/21447140","citation_count":27,"is_preprint":false},{"pmid":"27101204","id":"PMC_27101204","title":"High molecular weight hyaluronic acid regulates MMP13 expression in chondrocytes via DUSP10/MKP5.","date":"2016","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/27101204","citation_count":26,"is_preprint":false},{"pmid":"20633667","id":"PMC_20633667","title":"p38gamma mitogen-activated protein kinase suppresses chondrocyte production of MMP-13 in response to catabolic stimulation.","date":"2010","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/20633667","citation_count":26,"is_preprint":false},{"pmid":"38545904","id":"PMC_38545904","title":"Chondrocyte-Targeted Delivery System of Sortase A-Engineered Extracellular Vesicles Silencing MMP13 for Osteoarthritis Therapy.","date":"2024","source":"Advanced healthcare materials","url":"https://pubmed.ncbi.nlm.nih.gov/38545904","citation_count":26,"is_preprint":false},{"pmid":"26308852","id":"PMC_26308852","title":"RKIP Inhibits Local Breast Cancer Invasion by Antagonizing the Transcriptional Activation of MMP13.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26308852","citation_count":26,"is_preprint":false},{"pmid":"16112096","id":"PMC_16112096","title":"Focal cerebral ischemia induces changes in both MMP-13 and aggrecan around individual neurons.","date":"2005","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/16112096","citation_count":25,"is_preprint":false},{"pmid":"32767318","id":"PMC_32767318","title":"CircTMBIM6 promotes osteoarthritis-induced chondrocyte extracellular matrix degradation via miR-27a/MMP13 axis.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32767318","citation_count":25,"is_preprint":false},{"pmid":"30816475","id":"PMC_30816475","title":"circRNA‑CER mediates malignant progression of breast cancer through targeting the miR‑136/MMP13 axis.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30816475","citation_count":25,"is_preprint":false},{"pmid":"31677173","id":"PMC_31677173","title":"Matrix metalloproteinases MMP-1, MMP-2, and MMP-13 are overexpressed in primary nodular melanoma.","date":"2019","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31677173","citation_count":25,"is_preprint":false},{"pmid":"30352228","id":"PMC_30352228","title":"Design, cyclization, and optimization of MMP13-TIMP1 interaction-derived self-inhibitory peptides against chondrocyte senescence in osteoarthritis.","date":"2018","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/30352228","citation_count":25,"is_preprint":false},{"pmid":"26303573","id":"PMC_26303573","title":"Suppressed invasive and migratory behaviors of SW1353 chondrosarcoma cells through the regulation of Src, Rac1 GTPase, and MMP13.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26303573","citation_count":24,"is_preprint":false},{"pmid":"30348521","id":"PMC_30348521","title":"Low-intensity pulsed ultrasound induces cartilage matrix synthesis and reduced MMP13 expression in chondrocytes.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30348521","citation_count":24,"is_preprint":false},{"pmid":"36430655","id":"PMC_36430655","title":"Semaphorin 3A-Neuropilin-1 Signaling Modulates MMP13 Expression in Human Osteoarthritic Chondrocytes.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36430655","citation_count":23,"is_preprint":false},{"pmid":"18593760","id":"PMC_18593760","title":"Hsp90{beta} and p130(cas): novel regulatory factors of MMP-13 expression in human osteoarthritic chondrocytes.","date":"2008","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18593760","citation_count":23,"is_preprint":false},{"pmid":"25726157","id":"PMC_25726157","title":"The Expression and Significance of CXCR5 and MMP-13 in Colorectal Cancer.","date":"2015","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/25726157","citation_count":22,"is_preprint":false},{"pmid":"38061116","id":"PMC_38061116","title":"miR-99b-3p/Mmp13 axis regulates NLRP3 inflammasome-dependent microglial pyroptosis and alleviates neuropathic pain via the promotion of autophagy.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38061116","citation_count":22,"is_preprint":false},{"pmid":"28617559","id":"PMC_28617559","title":"Blockade of IL-17 alleviated inflammation in rat arthritis and MMP-13 expression.","date":"2017","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28617559","citation_count":21,"is_preprint":false},{"pmid":"30230587","id":"PMC_30230587","title":"CCL17-CCR4 axis promotes metastasis via ERK/MMP13 pathway in bladder cancer.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30230587","citation_count":21,"is_preprint":false},{"pmid":"20043086","id":"PMC_20043086","title":"ErbB2-enhanced invasiveness of H-Ras MCF10A breast cells requires MMP-13 and uPA upregulation via p38 MAPK signaling.","date":"2010","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20043086","citation_count":20,"is_preprint":false},{"pmid":"26057330","id":"PMC_26057330","title":"Cyclosporine A Downregulates MMP-3 and MMP-13 Expression in Cultured Pterygium Fibroblasts.","date":"2015","source":"Cornea","url":"https://pubmed.ncbi.nlm.nih.gov/26057330","citation_count":20,"is_preprint":false},{"pmid":"17941091","id":"PMC_17941091","title":"Ultrasound stimulates MMP-13 expression through p38 and JNK pathway in osteoblasts.","date":"2008","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17941091","citation_count":20,"is_preprint":false},{"pmid":"23519019","id":"PMC_23519019","title":"Effects of electro-acupuncture on oestrogen levels, body weight, articular cartilage histology and MMP-13 expression in ovariectomised rabbits.","date":"2013","source":"Acupuncture in medicine : journal of the British Medical Acupuncture Society","url":"https://pubmed.ncbi.nlm.nih.gov/23519019","citation_count":19,"is_preprint":false},{"pmid":"25190659","id":"PMC_25190659","title":"Keratocytes create stromal spaces to promote corneal neovascularization via MMP13 expression.","date":"2014","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/25190659","citation_count":19,"is_preprint":false},{"pmid":"33269546","id":"PMC_33269546","title":"Tgfb3 and Mmp13 regulated the initiation of liver fibrosis progression as dynamic network biomarkers.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33269546","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54549,"output_tokens":8380,"usd":0.144674},"stage2":{"model":"claude-opus-4-6","input_tokens":12233,"output_tokens":5204,"usd":0.286898},"total_usd":0.431572,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"The MMP13 gene is composed of 10 exons and 9 introns spanning over 12.5 kb. Its promoter contains a functional AP-1 site responsible for inducibility by tumor promoter TPA, an OSE-2 (osteoblast-specific element), a PEA-3 consensus sequence, and a TGF-β inhibitory element. DNA binding analysis confirmed formation of specific complexes between MMP13 promoter AP-1 sequences and nuclear proteins.\",\n      \"method\": \"Genomic cloning, nucleotide sequencing, transient transfection with CAT reporter constructs, DNA binding/EMSA with nuclear extracts\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct promoter characterization with functional reporter assays and DNA binding validation in multiple cell lines\",\n      \"pmids\": [\"9119388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RUNX2 overexpression in articular chondrocytes increases MMP-13 promoter activity and protein expression; FGF2 activates RUNX2 via MEK/ERK phosphorylation (~2-fold increase in RUNX2 phosphorylation), synergistically upregulating MMP-13. MEK/ERK inhibitors (PD98059) block this upregulation.\",\n      \"method\": \"RUNX2 overexpression, MMP-13 promoter activity assays, MEK/ERK inhibitor treatment, immunohistochemistry, Western blotting\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in a single study: promoter assays, pharmacological inhibition, phosphorylation analysis\",\n      \"pmids\": [\"15564063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Mechanical strain induces MMP-13 expression in osteoblastic cells through MEK-ERK1/2 signaling. The strain-induced MMP-13 mRNA expression does not require de novo protein synthesis. Dominant-negative MEK1/2 mutants block this induction.\",\n      \"method\": \"Biaxial strain application, Western blotting, RT-PCR, zymography, pharmacological inhibitors (PD98059, SB203580, SP600125), dominant-negative MEK1/2 transfection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including dominant-negative mutant validation and specific inhibitors\",\n      \"pmids\": [\"15044466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TGF-β activates Smad2/3 in head-and-neck SCC cells, and Smad3 signaling (including basal activation) drives MMP-13 expression and invasion. Disruption of Smad signaling by dominant-negative constructs or Smad7 overexpression suppresses MMP-13 expression and invasion through Matrigel and collagen I.\",\n      \"method\": \"Adenoviral delivery of Smad7, dominant-negative Smad3, kinase-defective ALK-5; Matrigel invasion assays; xenograft models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic loss-of-function approaches combined with in vitro and in vivo invasion assays\",\n      \"pmids\": [\"16407850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Lef1 and β-catenin synergistically upregulate MMP13 transcription in chondrocytes. A Lef1 binding site was mapped to the 3′ region of the MMP13 genomic locus; Lef1/β-catenin binding was confirmed by ChIP and EMSA. Lef1 siRNA knockdown suppressed IL-1β-mediated MMP13 expression.\",\n      \"method\": \"siRNA knockdown, ChIP, EMSA, MMP13 promoter reporter assays, plasmid transfection\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct promoter occupancy confirmed by ChIP and EMSA with functional siRNA validation\",\n      \"pmids\": [\"17971297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Nitric oxide (NO) causes tyrosine nitration of MMP-13 at residue Y338, which dissociates MMP-13 from caveolin-1, promoting its release from endothelial cells. In iNOS knockout mice, less MMP-13 is released and wound healing is slower; in caveolin-1 KO mice, increased MMP-13 nitration and accelerated wound healing are observed.\",\n      \"method\": \"Mutagenesis (Y338 identification), Co-IP (MMP-13/caveolin-1 association), iNOS and caveolin-1 knockout mouse models, wound healing assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — specific PTM site identified with genetic KO models providing functional validation in vivo\",\n      \"pmids\": [\"18495757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Ultrasound stimulation induces MMP-13 expression in osteoblasts via p38 and JNK signaling pathways (but not ERK). c-Fos and c-Jun bind to the AP-1 element on the MMP-13 promoter in response to ultrasound, enhancing AP-1 luciferase activity. Dominant-negative p38 or JNK mutants block this induction.\",\n      \"method\": \"Zymography, RT-PCR, AP-1 luciferase reporter assay, dominant-negative p38/JNK transfection, SB203580/SP600125 pharmacological inhibitors\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter reporter assays combined with dominant-negative mutant validation\",\n      \"pmids\": [\"17941091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Stroma-derived MMP-13 is required for melanoma tumor growth and organ-specific metastasis. Tumor growth was significantly impaired in mmp-13−/− mice, and metastasis to lungs, liver, and heart was substantially reduced. Decreased tumor growth correlated with reduced blood vessel density and decreased blood vessel permeability.\",\n      \"method\": \"Intradermal melanoma injection in MMP-13 knockout mice, MRI measurement of vessel permeability, immunohistochemistry of vascularity\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined metastatic phenotype and mechanistic link to angiogenesis\",\n      \"pmids\": [\"19516266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MMP13 amplification on chromosome 9A1 (syntenic with human 11q22) cooperates with p53 deficiency in osteosarcoma. High MMP13 expression enhances osteosarcoma cell survival; shRNA-mediated knockdown of MMP13 reduces tumor growth in immunodeficient mice.\",\n      \"method\": \"Array CGH, lentiviral shRNA knockdown, xenograft transplantation, microarray expression analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO/KD with defined tumor growth phenotype, but mechanism of survival enhancement not fully resolved\",\n      \"pmids\": [\"19276372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"p38γ isoform is activated by IL-1β and fibronectin fragments in chondrocytes but suppresses MMP-13 production; constitutively active p38γ decreases MMP-13 output while dominant-negative p38γ increases it. p38α (nuclear localized) promotes MMP-13 while p38γ (cytosolic) counteracts this.\",\n      \"method\": \"Constitutively active and dominant-negative p38γ transfection, isoform-selective inhibitors (SB203580, BIRB796), immunoblotting, ELISA, RT-PCR\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — gain- and loss-of-function with specific isoforms using multiple methods\",\n      \"pmids\": [\"20633667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Interstitial flow induces MMP-13 expression and cell motility in vascular smooth muscle cells via heparan sulfate proteoglycan (HSPG)-mediated FAK phosphorylation at Tyr925 and subsequent ERK1/2 activation. Disruption of HSPGs (heparinase or NDST1 silencing) or FAK inhibition abolishes this response.\",\n      \"method\": \"Heparinase treatment, NDST1 siRNA silencing, FAK inhibition/knockdown, ERK1/2 phosphorylation assays in 3D collagen culture\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal knockdown and pharmacological approaches with defined mechanistic pathway\",\n      \"pmids\": [\"21246051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MMP-13 directly promotes tumor angiogenesis by activating focal adhesion kinase (FAK) and ERK in endothelial cells, enhancing capillary tube formation in vitro and in vivo. MMP-13 also indirectly promotes angiogenesis by stimulating VEGF-A secretion from fibroblasts and endothelial cells.\",\n      \"method\": \"Conditioned medium assays, recombinant MMP-13 treatment, capillary tube formation assays in vitro and in vivo, FAK/ERK activation measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — both direct (recombinant protein) and indirect mechanisms tested with defined signaling readouts\",\n      \"pmids\": [\"22992737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Osterix physically interacts with Runx2 and cooperates with it to induce MMP13 expression during chondrocyte differentiation and endochondral ossification. Osterix-deficient mice arrest at the hypertrophic stage; introduction of MMP13 into Osterix-deficient limb bud cells restores matrix calcification.\",\n      \"method\": \"Global and conditional Osterix-KO mice, microarray analysis, Co-IP (Osterix-Runx2 interaction), adenoviral MMP13 rescue in deficient cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — physical interaction demonstrated by Co-IP, genetic KO with rescue experiment\",\n      \"pmids\": [\"22869368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Chondrocyte-specific deletion of Mmp13 (Mmp13Col2ER mice) decelerates OA progression, maintains higher cartilage area/thickness and type II collagen/proteoglycan levels, and reduces chondrocyte apoptosis. Pharmacological inhibition of MMP13 with CL82198 (confirmed by ELISA to inhibit >85% activity) recapitulates these protective effects.\",\n      \"method\": \"Conditional chondrocyte-specific Mmp13 knockout (Col2CreER), meniscal-ligamentous injury OA model, ELISA-based MMP13 activity assay, histology/histomorphometry, TUNEL staining\",\n      \"journal\": \"Arthritis research & therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with multiple histological readouts plus pharmacological validation\",\n      \"pmids\": [\"23298463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Knee loading reduces MMP13 activity in OA mouse cartilage through Rac1 GTPase-mediated p38 MAPK and NF-κB signaling. Silencing Rac1 reduces MMP13 expression and p-p38; constitutively active Rac1 increases and dominant-negative Rac1 decreases MMP13 activity.\",\n      \"method\": \"Mouse knee loading model, FRET-based Rac1 activity imaging, siRNA knockdown, constitutively active/dominant-negative Rac1 transfection, MMP13 activity assay, immunoblotting\",\n      \"journal\": \"BMC musculoskeletal disorders\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — FRET live imaging combined with genetic gain/loss-of-function approaches\",\n      \"pmids\": [\"24180431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MMP-13 shows substrate selectivity for collagen II over collagens I and III, binding specifically to two triple-helical peptides in Collagen Toolkit II (peptides II-44 and II-8). Binding requires the triple-helical conformation (MMP-13 cannot bind linear peptide). The hemopexin domain (not the free catalytic subunit) mediates this binding; the canonical cleavage site in collagen II is at Gly775-Leu776.\",\n      \"method\": \"Triple-helical peptide Collagen Toolkit libraries, solid-phase binding assays, proteolysis assays with recombinant proMMP-13, MMP-13, free hemopexin domain, and free catalytic subunit\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with structural domain dissection and defined cleavage site identification\",\n      \"pmids\": [\"25008319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ANKRD1 acts as a transcriptional repressor of MMP13 via the AP-1 site on the MMP13 promoter, operating in association with nucleolin (identified by yeast two-hybrid and Co-IP). Ankrd1 deletion increases c-Jun binding to the MMP13 AP-1 site (shown by ChIP), elevates MMP13 mRNA and protein in skin and wounds.\",\n      \"method\": \"Yeast two-hybrid, Co-IP, ChIP, EMSA, MMP13 promoter activity assays, Ankrd1 KO mice, siRNA knockdown, Ankrd1 reconstitution\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including ChIP, Co-IP, and genetic KO with reconstitution\",\n      \"pmids\": [\"24515436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GDF5 reduces MMP13 expression in human chondrocytes via induction of the canonical Wnt inhibitor DKK1. Inhibition of DKK1 by a small molecule (WAY-262621) reverses GDF5-mediated suppression of MMP13, establishing DKK1 as the intermediate mediator.\",\n      \"method\": \"Pellet mass culture system, qPCR, ELISA, Wnt pathway agonists (Wnt3a, CHIR-99021), DKK1 small molecule inhibitor (WAY-262621), siRNA knockdown\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pathway validated with both pharmacological activation and specific inhibition at multiple nodes\",\n      \"pmids\": [\"24561281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MMP13 promotes colorectal cancer metastasis to the liver: both stromal (host) and tumor-derived MMP13 contribute to tumor cell extravasation from hepatic vasculature. MMP13 deficiency in host mice or stable MMP13 knockdown in tumor cells reduces extravasation and metastatic burden in vivo. MMP13 upregulation in steatotic liver increases metastatic burden.\",\n      \"method\": \"Splenic injection liver metastasis model in Mmp13-deficient mice, stable shRNA knockdown cell lines, whole-organ confocal microscopy, MTT/migration/invasion assays\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO host model combined with tumor-cell-specific knockdown and direct visualization of extravasation\",\n      \"pmids\": [\"25880591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SENP2 inhibits MMP13 expression in bladder cancer cells by de-SUMOylating TBL1/TBLR1, which prevents β-catenin nuclear translocation and thereby reduces MMP13 transcriptional activation by β-catenin at the MMP13 promoter.\",\n      \"method\": \"SENP2 overexpression/knockdown, TBL1/TBLR1 SUMOylation assays, β-catenin nuclear translocation assays, luciferase promoter assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined PTM (de-SUMOylation) linked to downstream MMP13 regulation, single study\",\n      \"pmids\": [\"26369384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ATF3 directly binds the proximal AP-1 motif of the MMP13 promoter in stimulated human chondrocytes at time points after transient cFOS binding has ceased, acting as a direct transcriptional activator. cFOS plays an earlier, indirect role. ATF3 expression itself is AP-1 (cFOS/cJUN)-dependent, creating a regulatory cascade.\",\n      \"method\": \"ChIP assays for promoter occupancy, siRNA-mediated ATF3 silencing, mRNA transcriptome analysis, protein synthesis inhibition experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct promoter occupancy by ChIP combined with specific siRNA silencing and transcriptome validation\",\n      \"pmids\": [\"27956552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ETV4 directly regulates MMP13 gene transcription, and MMP13 mediates ETV4-driven proliferation, migration, invasion, and anchorage-independent growth in mammary epithelial cells. MMP13 inhibition partially blocks ETV4-induced tumor formation in immunodeficient mice.\",\n      \"method\": \"MMP13 promoter reporter constructs, gain/loss-of-function for ETV4 and MMP13 in cell lines and xenografts\",\n      \"journal\": \"Breast cancer research : BCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter regulation shown with functional rescue/inhibition, single study\",\n      \"pmids\": [\"29996935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FGF23 drives MMP13 expression in OA chondrocytes through FGFR1 in a Klotho-independent manner, predominantly via MEK/ERK cascade with lesser PI3K/AKT contribution. RNA silencing of FGFR1 (but not Klotho) blocks FGF23-induced MMP13 upregulation.\",\n      \"method\": \"siRNA silencing of FGFR1 and Klotho, phosphoprotein array, immunoblotting, selective MAPK inhibitors, fluorescent MMP13 activity assay, immunohistochemistry\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (siRNA, inhibitors, activity assay) establishing receptor specificity\",\n      \"pmids\": [\"27307356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DNA methylation of specific CpG sites in the RUNX2 P1 promoter controls RUNX2 expression; reduced methylation increases RUNX2 availability which transactivates MMP13. RUNX2 overexpression enhanced MMP13 promoter activity independently of MMP13 promoter methylation status.\",\n      \"method\": \"qPCR correlation in human OA chondrocytes, RUNX2 overexpression, in vitro methylation treatment of RUNX2 promoter constructs, MMP13 promoter reporter assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epigenetic mechanism demonstrated with functional promoter assays, moderate evidence\",\n      \"pmids\": [\"28798419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Osteocyte-derived MMP13 is required for perilacunar/canalicular remodeling (PLR) in subchondral bone. Osteocyte-specific Mmp13 ablation (DMP1-Cre) suppresses PLR, disorganizes bone extracellular matrix, and secondarily impairs cartilage homeostasis (reduced proteoglycan, altered collagen II, increased cartilage lesions), demonstrating a bone-cartilage crosstalk mediated by osteocytic MMP13.\",\n      \"method\": \"Osteocyte-specific Cre-mediated Mmp13 conditional KO (DMP1-Cre), histomorphometry, IHC, without surgical injury model\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific genetic KO with multiple defined skeletal phenotypes in both human OA specimens and mouse models\",\n      \"pmids\": [\"31700695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Bleomycin-induced lung fibrosis resolves more slowly and more severely in Mmp13-null mice, with decreased overall collagenolytic activity and persistent fibrotic foci. MMP13 is expressed mainly by macrophages during inflammation and fibrosis resolution phases, establishing an antifibrotic role for MMP13.\",\n      \"method\": \"Mmp13 knockout mice, bleomycin intratracheal instillation, bronchoalveolar lavage cytokine array, gelatinase activity assays, histology\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with well-defined fibrosis resolution phenotype and biochemical activity measurement\",\n      \"pmids\": [\"30785343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MMP13 cleaves and remodels type I collagen matrix to expose cryptic ligands that bind integrin α3 (ITGA3), activating FAK and RUNX2 in mesenchymal stem cells to drive osteogenic differentiation. RUNX2 in turn binds the MMP13 promoter to upregulate MMP13, forming a positive feedback loop (MMP13/ITGA3/RUNX2).\",\n      \"method\": \"MMP13 knockdown, recombinant MMP13 pre-treatment of collagen matrix, ITGA3 expression analysis, RUNX2 ChIP on MMP13 promoter, in vivo bone formation assays\",\n      \"journal\": \"Acta biomaterialia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro reconstitution of collagen cleavage, ChIP demonstrating RUNX2 binding to MMP13 promoter, in vivo validation\",\n      \"pmids\": [\"33677160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Hsp90β and p130(cas) are identified as regulatory proteins that bind the AGRE site of the MMP-13 promoter in L-OA chondrocytes (identified by mass spectrometry). Silencing Hsp90β or p130(cas) significantly increases MMP-13 expression and production; combined silencing has an additive effect. IL-1β decreases p130(cas) and Hsp90β expression, providing a mechanism for cytokine-driven MMP-13 upregulation.\",\n      \"method\": \"Mass spectrometry identification of promoter-binding proteins, siRNA knockdown of Hsp90β/p130(cas)/NMP4, ELISA, RT-PCR, Western blotting\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mass spectrometry-identified regulatory proteins with siRNA functional validation, single study\",\n      \"pmids\": [\"18593760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"High molecular weight hyaluronic acid (HA) inhibits TNF-α-induced MMP13 expression in chondrocytes via CD44 interaction, which induces DUSP10/MKP5 (a negative regulator of p38 MAPK and JNK), thereby suppressing AP-1 transcriptional activity. CD44 blocking antibody abolishes HA-mediated MMP13 inhibition.\",\n      \"method\": \"CD44-blocking antibody, HA treatment, p38/JNK phosphorylation assays, AP-1 reporter assay, DUSP10/MKP5 expression analysis by RT-PCR, western blot, immunofluorescence\",\n      \"journal\": \"Journal of orthopaedic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissected with specific receptor blockade and downstream phosphatase induction, single study\",\n      \"pmids\": [\"27101204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Angiotensin II activates MMP8 and MMP13 in atherosclerotic plaques with vulnerable phenotype, leading to increased collagen type I degradation and intra-plaque hemorrhage. ATII treatment increased MMP13 levels 2-fold and collagen I degradation by MMP13 3-fold in vulnerable upstream lesions.\",\n      \"method\": \"Extravascular device carotid artery model in ApoE KO mice with ATII infusion, immunohistochemistry for MMP8/MMP13 activity, collagen content assessment, MRI\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mouse model with quantified enzyme activity and collagen degradation, single study\",\n      \"pmids\": [\"19233360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL-17A induces MMP-13 expression and activation in human aortic smooth muscle cells via TRAF3IP2-dependent JNK, p38 MAPK, AP-1, and NF-κB activation. Recombinant MMP-13 stimulates SMC migration via ERK. RECK (membrane-anchored inhibitor) overexpression attenuates MMP-13 activity (without affecting mRNA/protein), blocking IL-17A- and MMP-13-induced SMC migration.\",\n      \"method\": \"TRAF3IP2 knockdown/overexpression, recombinant MMP-13 treatment, RECK gain-of-function, kinase activation assays, SMC migration assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined signaling pathway with both upstream (TRAF3IP2) and downstream (RECK) modulation tested\",\n      \"pmids\": [\"31074012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MMP-2 and MMP-13 have opposing roles in vasculogenic mimicry (VM) in large cell lung cancer. MMP-2 cleaves laminin-5 (Ln-5) to generate fragments that promote VM by activating EGFR/F-actin, while MMP-13 cleaves Ln-5 to generate different fragments that decrease EGFR/F-actin expression and disrupt VM formation.\",\n      \"method\": \"MMP-13 overexpression, recombinant MMP-13 treatment, 3D culture tube formation assays, xenograft tumor models, immunohistochemistry\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — both recombinant protein and overexpression approaches with defined downstream signaling, single study\",\n      \"pmids\": [\"28766880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"VEGFc/VEGFr3 signaling induces MMP13 expression in keratocytes (via MMP13 promoter luciferase assay). Keratocyte-derived MMP13 directly degrades type I collagen, creating stromal spaces that enable corneal neovascularization. A selective MMP13 inhibitor attenuates alkali-burn-induced corneal neovascularization.\",\n      \"method\": \"qRT-PCR, Western blot, in situ hybridization, luciferase MMP13 promoter assay, hydroxyproline content assay, selective MMP13 inhibitor treatment, immunohistochemistry\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter regulation, collagen degradation, and pharmacological inhibition in a defined in vivo model\",\n      \"pmids\": [\"25190659\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MMP13 (collagenase-3) is a zinc-dependent extracellular endopeptidase that preferentially cleaves type II collagen at Gly775-Leu776 using its hemopexin domain for substrate recognition and its catalytic domain for cleavage; its transcription is regulated at a promoter containing functional AP-1, RUNX2/OSE-2, Lef1/β-catenin, and Smad binding sites, with positive inputs from RUNX2/Osterix, ATF3, ETV4, FGF23-FGFR1-ERK, IL-1β-TAK1, Rac1-p38α-NF-κB, and Wnt/Lef1 pathways, and negative regulation by p130(cas)/Hsp90β, ANKRD1-nucleolin, HA-CD44-DUSP10/MKP5, and p38γ; post-translationally, NO-driven Y338 nitration releases MMP13 from caveolin-1 storage in endothelial cells; in bone, osteocyte-derived MMP13 maintains perilacunar/canalicular remodeling and indirectly supports cartilage homeostasis; in tissue repair and cancer, secreted MMP13 remodels collagen ECM, promotes angiogenesis via FAK-ERK activation and VEGF-A release, and facilitates tumor cell extravasation and metastasis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MMP13 (collagenase-3) is a zinc-dependent matrix metalloproteinase that cleaves fibrillar collagens—with marked preference for type II collagen at Gly775-Leu776—using its hemopexin domain for triple-helical substrate recognition and its catalytic domain for hydrolysis, thereby remodeling extracellular matrix in bone, cartilage, vasculature, and wound repair [PMID:25008319, PMID:23298463, PMID:31700695]. Transcription of MMP13 is driven by a promoter containing functional AP-1, RUNX2/OSE-2, Lef1/β-catenin, and Smad-responsive elements, integrating signals from MEK-ERK (via RUNX2 phosphorylation, FGF23-FGFR1, mechanical strain), p38α-JNK-NF-κB (via Rac1, IL-1β), Wnt/β-catenin (via Lef1), TGF-β-Smad3, and direct binding of ATF3 and ETV4; transcriptional repression is mediated by ANKRD1-nucleolin at the AP-1 site, Hsp90β/p130Cas at the AGRE element, p38γ antagonism, and HA-CD44-DUSP10 axis suppressing MAPK [PMID:9119388, PMID:15564063, PMID:17971297, PMID:27956552, PMID:24515436, PMID:20633667, PMID:27101204]. Post-translationally, nitric oxide–driven nitration of Tyr338 releases MMP13 from caveolin-1 storage in endothelial cells, controlling its secretion during wound healing [PMID:18495757]. In vivo, osteocyte-derived MMP13 maintains perilacunar/canalicular remodeling and cartilage integrity, chondrocyte MMP13 drives osteoarthritis cartilage destruction, macrophage-expressed MMP13 promotes lung fibrosis resolution, and stromal/tumor-derived MMP13 facilitates angiogenesis via FAK-ERK activation and VEGF-A release and enables tumor extravasation and metastasis [PMID:31700695, PMID:23298463, PMID:30785343, PMID:22992737, PMID:25880591].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Defining the transcriptional architecture of MMP13 established that its inducibility is controlled through a modular promoter with AP-1, OSE-2, PEA-3, and TGF-β-inhibitory elements, providing the framework for understanding how diverse stimuli converge on MMP13 expression.\",\n      \"evidence\": \"Genomic cloning, CAT reporter assays, and EMSA with nuclear extracts in multiple cell lines\",\n      \"pmids\": [\"9119388\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each promoter element in physiological contexts was not resolved\", \"Chromatin-level regulation not addressed\", \"No in vivo promoter validation\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrating that mechanical strain and growth factor (FGF2) signals converge on MEK-ERK to activate MMP13 transcription—via RUNX2 phosphorylation in chondrocytes and direct transcriptional induction in osteoblasts—established the ERK-MAPK axis as a central upstream regulator of MMP13.\",\n      \"evidence\": \"RUNX2 overexpression with promoter assays, MEK inhibitors (PD98059), dominant-negative MEK1/2, biaxial strain in osteoblastic cells\",\n      \"pmids\": [\"15564063\", \"15044466\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of ERK substrates directly binding the MMP13 promoter beyond RUNX2 not resolved\", \"Relative contributions of RUNX2-dependent vs. -independent ERK targets unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showing that TGF-β/Smad3 signaling drives MMP13 expression and invasion in squamous carcinoma cells revealed a second major transcriptional axis (independent of MEK-ERK) through which MMP13 promotes cancer cell invasiveness.\",\n      \"evidence\": \"Dominant-negative Smad3, Smad7 overexpression, kinase-defective ALK-5, Matrigel invasion assays, xenografts\",\n      \"pmids\": [\"16407850\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Smad3 occupancy of MMP13 promoter not shown by ChIP\", \"Cross-talk between Smad and AP-1 pathways at MMP13 not addressed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of a functional Lef1/β-catenin binding site and ChIP-confirmed occupancy at the MMP13 locus established the Wnt pathway as a direct transcriptional activator of MMP13, later reinforced by evidence that β-catenin nuclear translocation (regulated by SENP2/TBL1) controls MMP13 in cancer cells.\",\n      \"evidence\": \"ChIP, EMSA, siRNA knockdown of Lef1 in chondrocytes; SENP2/TBL1 SUMOylation assays and β-catenin translocation in bladder cancer cells\",\n      \"pmids\": [\"17971297\", \"26369384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Lef1 and RUNX2 cooperate or compete at the MMP13 promoter is unknown\", \"Wnt ligand specificity for MMP13 induction in vivo not established\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that NO-mediated Tyr338 nitration dissociates MMP13 from caveolin-1, promoting its secretion from endothelial cells during wound healing, revealed the first post-translational mechanism controlling MMP13 release rather than transcription.\",\n      \"evidence\": \"Y338 mutagenesis, Co-IP of MMP13/caveolin-1, iNOS-KO and caveolin-1-KO mice with wound healing assays\",\n      \"pmids\": [\"18495757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Y338 nitration affects catalytic activity in addition to secretion is unknown\", \"Applicability beyond endothelial cells not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Parallel studies revealed additional MAPK route diversity: ultrasound-induced MMP13 in osteoblasts depends on p38/JNK (not ERK), and angiotensin II activates MMP13 in atherosclerotic plaques, expanding the pathophysiological contexts of MMP13 regulation beyond cartilage and bone.\",\n      \"evidence\": \"Dominant-negative p38/JNK with AP-1 reporters in osteoblasts; ATII infusion in ApoE-KO carotid model with MMP13 IHC\",\n      \"pmids\": [\"17941091\", \"19233360\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stimulus-specific selection of p38/JNK vs. ERK at the MMP13 promoter not mechanistically explained\", \"ATII-MMP13 link not validated by genetic ablation\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"MMP13-knockout host mice showed impaired melanoma growth, reduced metastasis, and decreased angiogenesis, establishing that stroma-derived MMP13 is functionally required for tumor vascularization and organ-specific metastatic colonization.\",\n      \"evidence\": \"Intradermal melanoma injection in global Mmp13-KO mice, MRI vessel permeability, IHC\",\n      \"pmids\": [\"19516266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific MMP13 substrates mediating vascular permeability not identified\", \"Tumor-cell-autonomous vs. stromal MMP13 not dissected in this model\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrating that p38γ opposes p38α in suppressing MMP13 output in chondrocytes established isoform-specific MAPK antagonism as a fine-tuning mechanism, explaining why global p38 inhibitors do not simply reduce MMP13.\",\n      \"evidence\": \"Constitutively active and dominant-negative p38γ constructs, isoform-selective inhibitors, ELISA in chondrocytes\",\n      \"pmids\": [\"20633667\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct p38γ phosphorylation targets that mediate MMP13 suppression not identified\", \"In vivo relevance of p38γ-mediated MMP13 regulation not shown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Recombinant MMP13 directly activates FAK and ERK in endothelial cells to promote tube formation and indirectly stimulates VEGF-A secretion, defining a dual (direct + indirect) pro-angiogenic mechanism that explains the vascular phenotype of MMP13-KO tumors.\",\n      \"evidence\": \"Recombinant MMP13 treatment, FAK/ERK phosphorylation, capillary tube assays in vitro and in vivo\",\n      \"pmids\": [\"22992737\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The MMP13 substrate(s) that generate FAK-activating ligands in endothelial cells are unidentified\", \"Whether catalytic activity or protein-protein interaction drives FAK activation is unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Osterix physically interacts with RUNX2 (by Co-IP) and cooperates to drive MMP13 during endochondral ossification; adenoviral MMP13 rescue of Osterix-KO cells restores matrix calcification, placing MMP13 as a critical RUNX2/Osterix effector in skeletal development.\",\n      \"evidence\": \"Global and conditional Osterix-KO mice, Co-IP, adenoviral MMP13 rescue in limb bud cells\",\n      \"pmids\": [\"22869368\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Osterix directly contacts the MMP13 promoter or acts solely through RUNX2 is unresolved\", \"Osterix-RUNX2 binding interface not structurally characterized\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Chondrocyte-specific Mmp13 deletion decelerates osteoarthritis progression (preserving collagen II and proteoglycan and reducing apoptosis), directly establishing MMP13 as a disease-driving collagenase in OA cartilage and validating it as a therapeutic target.\",\n      \"evidence\": \"Conditional Col2CreER Mmp13 KO, meniscal-ligamentous OA model, pharmacological validation with CL82198, histomorphometry\",\n      \"pmids\": [\"23298463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MMP13 inhibition is sufficient long-term or whether compensatory collagenases emerge is unknown\", \"Anti-apoptotic effect could be indirect via ECM preservation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Biochemical dissection with triple-helical peptide toolkits showed MMP13 preferentially binds collagen II over collagens I/III through its hemopexin domain recognizing specific triple-helical motifs, with canonical cleavage at Gly775-Leu776, resolving the structural basis for substrate selectivity.\",\n      \"evidence\": \"Solid-phase binding with Collagen Toolkit peptide libraries, proteolysis assays with recombinant domains\",\n      \"pmids\": [\"25008319\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length collagen II–MMP13 co-crystal structure unavailable\", \"How collagen cross-linking or post-translational modifications affect recognition unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of ANKRD1-nucleolin as a repressive complex at the MMP13 AP-1 site (by yeast two-hybrid, Co-IP, and ChIP) and of Hsp90β/p130Cas as repressors at the AGRE element revealed dedicated negative regulatory mechanisms that are relieved by cytokine stimulation.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, ChIP showing increased c-Jun binding in Ankrd1-KO; mass spectrometry, siRNA of Hsp90β/p130Cas in chondrocytes\",\n      \"pmids\": [\"24515436\", \"18593760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ANKRD1-nucleolin and Hsp90β/p130Cas interact or regulate independently is unknown\", \"Structural basis for ANKRD1 displacement of c-Jun not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Using MMP13-deficient hosts and tumor-cell-specific knockdown in a liver metastasis model, both stromal and tumor-derived MMP13 were shown to promote colorectal cancer extravasation, extending MMP13's metastatic role beyond melanoma to epithelial cancers with tissue-specific effects.\",\n      \"evidence\": \"Splenic injection model in Mmp13-KO mice, stable shRNA in tumor cells, whole-organ confocal imaging\",\n      \"pmids\": [\"25880591\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MMP13 substrates facilitating trans-endothelial migration not identified\", \"Whether MMP13 acts on endothelial junctions or basement membrane in this context is unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"ChIP-based temporal mapping revealed that ATF3 (not c-Fos) is the sustained direct occupant of the MMP13 AP-1 site after stimulation, with ETV4 independently shown to directly activate MMP13 transcription in breast epithelial cells, diversifying the set of known direct transcriptional activators.\",\n      \"evidence\": \"Time-resolved ChIP for ATF3/cFOS occupancy with siRNA in chondrocytes; ETV4 gain/loss-of-function with MMP13 promoter reporters in mammary cells\",\n      \"pmids\": [\"27956552\", \"29996935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ATF3 and ETV4 cooperate in any shared cell type is unknown\", \"Genome-wide enhancer elements driving MMP13 beyond the proximal promoter not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"FGF23 was shown to drive MMP13 in chondrocytes through FGFR1 (Klotho-independent) predominantly via MEK/ERK, and HA-CD44-DUSP10/MKP5 axis was identified as suppressing MMP13 by dephosphorylating p38/JNK, adding receptor-level specificity to both inductive and suppressive arms of MMP13 regulation.\",\n      \"evidence\": \"FGFR1/Klotho siRNA with phosphoprotein arrays; CD44 blocking antibody, DUSP10 expression analysis in chondrocytes\",\n      \"pmids\": [\"27307356\", \"27101204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo importance of FGF23 vs. FGF2 in OA-associated MMP13 upregulation not established\", \"Whether DUSP10 directly dephosphorylates p38α at the MMP13 promoter complex is unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Osteocyte-specific Mmp13 ablation (DMP1-Cre) impaired perilacunar/canalicular remodeling and secondarily degraded cartilage homeostasis, establishing that osteocyte-derived MMP13 maintains the bone-cartilage unit through subchondral matrix turnover.\",\n      \"evidence\": \"Conditional DMP1-Cre Mmp13 KO mice, histomorphometry, IHC of bone and cartilage\",\n      \"pmids\": [\"31700695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular signals from osteocytes to chondrocytes disrupted by PLR failure are unknown\", \"Whether lactation-induced PLR also requires MMP13 not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mmp13-null mice showed exacerbated bleomycin-induced lung fibrosis with reduced collagenolytic activity, revealing an anti-fibrotic role for macrophage-derived MMP13 in fibrosis resolution—opposite to its cartilage-destructive role in OA.\",\n      \"evidence\": \"Global Mmp13-KO, bleomycin model, BAL cytokine array, gelatinase activity assays\",\n      \"pmids\": [\"30785343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MMP13 directly cleaves lung collagen or acts through activation of other MMPs is not resolved\", \"Specific macrophage subtype expressing MMP13 not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"MMP13 cleavage of type I collagen exposes cryptic integrin α3 ligands that activate FAK-RUNX2, which in turn transactivates MMP13, establishing a self-amplifying positive feedback loop (MMP13→ITGA3→FAK→RUNX2→MMP13) in osteogenic differentiation.\",\n      \"evidence\": \"Recombinant MMP13 pre-treatment of collagen matrix, ITGA3 analysis, RUNX2 ChIP on MMP13 promoter, in vivo bone formation\",\n      \"pmids\": [\"33677160\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific cryptic collagen I peptide sequences recognized by ITGA3 not identified\", \"Whether this feedback loop operates in pathological bone remodeling (e.g., metastatic lesions) is untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for MMP13 hemopexin domain recognition of collagen II triple helix, the identity of MMP13-generated fragments that activate endothelial FAK during angiogenesis, how tissue context (cartilage vs. lung vs. tumor stroma) determines whether MMP13 activity is destructive or protective, and whether therapeutic MMP13 inhibition can achieve tissue-selective effects.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No co-crystal structure of MMP13 hemopexin domain with collagen II\", \"Angiogenic substrate fragments not identified biochemically\", \"No systems-level model integrating transcriptional, post-translational, and feedback regulation of MMP13 across tissues\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [15, 26]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [13, 15, 25, 29, 32]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [5, 7, 11, 15, 18, 25, 26, 29]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [15, 24, 26, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [13, 15, 24, 25, 26, 29, 32]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 3, 4, 9, 10, 14, 22, 30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 8, 18, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RUNX2\",\n      \"CAV1\",\n      \"ANKRD1\",\n      \"NCL\",\n      \"LEF1\",\n      \"CTNNB1\",\n      \"SP7\",\n      \"ATF3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}